posted on 2021-02-01, 22:05authored byArik J. Hone, Quentin Kaas, Ireland Kearns, Fuaad Hararah, Joanna Gajewiak, Sean Christensen, David J. Craik, J. Michael McIntosh
Nicotinic acetylcholine receptors
(nAChRs) are pharmacological
targets for the treatment of neuropathic pain, and the α6β4
subtype has been identified as particularly promising. Rat α6β4
nAChRs are less sensitive to some ligands than the human homologue
potentially complicating the use of rodent α6β4 receptors
for screening therapeutic compounds. We used molecular dynamics simulations
coupled with functional assays to study the interaction between α-conotoxin
PeIA and α6β4 nAChRs and to identify key ligand–receptor
interactions that contribute to species differences in α-conotoxin
potency. Our results show that human and rat α6β4 nAChRs
have distinct ligand-binding motifs and show markedly different sensitivities
to α-conotoxins. These studies facilitated the creation of PeIA-5667,
a peptide that shows 270-fold higher potency for rat α6β4
nAChRs over native PeIA and similar potency for the human homologue.
Our results may inform the design of therapeutic ligands that target
α6β4 nAChRs for the treatment of neuropathic pain.